

January 31, 2026

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir/Madam,

Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Regulatory action/ inspection

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby submit the disclosure regarding a search and seizure/investigation operation conducted by the Goods & Service Tax Department, Mumbai, Maharashtra, at the Offices of the Company. The operation commenced on January 27, 2025, at 12.30 p.m. and concluded on January 31, 2026, at 7.00 p.m.

The relevant details as required pursuant to Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are provided in “**Annexure A**”, enclosed herewith.

The Company has fully cooperated with the officials throughout the proceedings, providing all necessary documents, clarifications and details as requested. We will continue to extend our support and furnish any further information as may be required.

You are requested to take the above information on your records.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Encl: As above

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Annexure-A

Disclosure under Para A of Schedule III to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No.	Particulars	Information
1	Name of the Authority	Assistant Commissioner of State Tax (CST-INV-D-0214), Investigation – B, Mumbai
2	Nature and details of the action(s) taken, initiated or order(s) passed	Search/inspection under Section 67 of the Maharashtra Goods and Services Tax Act, 2017
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	The operation commenced on January 27, 2026, at 12.30 p.m. and concluded on January 31, 2026 at 7.00 p.m.
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	The Company has provided all necessary documents, clarifications and details, as requested. Further, no official document has been issued w.r.t. any adverse findings.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.	There is no material impact on the Company's financials, operations or other activities, due to said inspection.

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com